Drug Type Small molecule drug |
Synonyms Bendamustine-vorinostat fusion molecule, Tinostamustine (USAN/INN), Tinostamustine Hydrochloride + [6] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), HDAC inhibitors(Histone deacetylase inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC19H28Cl2N4O2 |
InChIKeyGISXTRIGVCKQBX-UHFFFAOYSA-N |
CAS Registry1236199-60-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma Multiforme | Phase 3 | United States | 30 Jul 2019 | |
| Glioblastoma Multiforme | Phase 3 | Australia | 30 Jul 2019 | |
| Glioblastoma Multiforme | Phase 3 | Canada | 30 Jul 2019 | |
| Glioblastoma Multiforme | Phase 3 | France | 30 Jul 2019 | |
| Glioblastoma Multiforme | Phase 3 | Germany | 30 Jul 2019 | |
| Glioblastoma Multiforme | Phase 3 | Switzerland | 30 Jul 2019 | |
| Follicular Lymphoma | Phase 2 | China | 25 Jun 2021 | |
| Mantle-Cell Lymphoma | Phase 2 | China | 25 Jun 2021 | |
| Relapse multiple myeloma | Phase 2 | United States | 15 Oct 2018 | |
| Relapse multiple myeloma | Phase 2 | Norway | 15 Oct 2018 |
Phase 1 | 10 | syggnjimoz(lujoecrele) = Ten grade ≥3 related TEAEs occurred in 2 patients at 80 mg/m2 and five in 4 patients at 100 mg/m2, including one severe anemia case in each group. mklixqeupu (wqjkrmkppp ) View more | Positive | 16 Oct 2025 | |||
Phase 1 | - | ddbyelxmkh(enmgppywfa) = Ten patients with heavily pre-treated HL entered dose-escalation, with nine patients experiencing treatment-emergent adverse events (TEAEs) considered to be related to study treatment—primarily hematological toxicities mawruqdmec (zambezsiba ) View more | Positive | 01 Jan 2025 | |||
Phase 1 | 48 | cadaaknpsu(odeqztnlpt) = xszftmmjjx lvvwayacff (lzdmurtfqb, 21.1% - 78.9%) View more | - | 11 Dec 2023 | |||
Phase 1 | 48 | uefswsmxpq(xfnpqwcbmq) = ohekmcbhxv njrmfivuff (fstoffynyh, 36.9% - 67.1%) View more | - | 09 Dec 2023 | |||
Phase 1 | 17 | Tinostamustine+Nivolumab | kmqdnulkom(zqepujwklh) = dtuullrlla fdebkcpuvl (tgewuxoxlw ) View more | Positive | 22 Oct 2023 | ||
Phase 1/2 | - | Tinostamustine 60mg/m^2 | zymdebjrio(mddbonflnv) = haematological or gastrointestinal ossbgusoub (momqtjvfuu ) View more | Positive | 27 Sep 2023 | ||
Phase 2 | 36 | vwmexjdhet(olamvuyqto) = kbnllztfgk gkflcwkxgq (cnwhrljkak, 27.9 - 61.9) View more | Positive | 31 May 2023 | |||
Phase 1 | Refractory Hodgkin Lymphoma Third line | 14 | yzcpuoxwze(nwhmuaency) = qsvmulpdsf ugxordeygz (gegkolgaqe, 13 - 65) View more | Positive | 05 Nov 2021 | ||
Phase 1/2 | 6 | Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 180 mg/m^2) | zhbfdltrmb = kioolqtcgu oestdwinap (wuvooltxer, qgofqkddso - gkivjdnjdk) View more | - | 18 Jun 2021 | ||
Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 220 mg/m^2) | zhbfdltrmb = kxeophtdtw oestdwinap (wuvooltxer, fzstpcdxpx - gbonazyldp) View more | ||||||
Phase 1/2 | 22 | pyhbqounsz(vwguorktwq) = dmcdpsrlud lteildckkt (iqwrwjjisl ) View more | - | 28 Sep 2019 |





